SureTrader Advertisement SureTrader
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Recall Merck also tried to get an "improved

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
genisi Member Profile
 
Followed By 32
Posts 5,196
Boards Moderated 0
Alias Born 05/24/06
160x600 placeholder
Stocks Trim Losses As Strong Services-sector Data Spark Some Risk Appetite
But private-payroll gains miss expectations; productivity falls U.S. stocks trimmed early losses Wednesday, after a gauge of activity in...
Top Equities Stories Of The Day
Correction to Fitbit Jawbone Article on April 29
Deutsche Bank North America CEO Jacques Brand to Leave for PJT Partners
Ackman: No Plans to Sell Any Valeant `Crown Jewel' Assets -CNBC
Brazilian Judge Lifts WhatsApp Ban -- Update
Auto Sales Spring Ahead -- WSJ
Oil Pares Gains on Big Rise in Inventories
Gilead Seeks to Tame Merck Case -- WSJ
Zillow Beats Expectations, Lifts Sales View
genisi   Wednesday, 04/27/11 03:49:51 AM
Re: biomaven0 post# 118902
Post # of 201146 
Recall Merck also tried to get an "improved niacin" by targeting the same receptor with MK-0354, which despite significant decreases in FFAs levels and absence of flushing failed to demonstrate effects on HDL/LDL-Cholesterol and TGs in phase II. Obviously, being a GPR109A receptor agonist isn't all.

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist